mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-1-32-37mrj-1097Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSРиск переломов и потребность в антиостеопоротическом лечении у больных системной склеродермиейThe risk of fractures and the need for anti-osteoporotic treatment in patients with systemic sclerosishttps://orcid.org/0000-0002-8155-6101ЕфремоваА. О.EfremovaA. О.

Арина Олеговна Ефремова

115522, Москва, Каширское шоссе, 34А

 

Arina Olegovna Efremova

34A, Kashirskoe Shosse, Moscow 115522

ari1903@mail.ruhttps://orcid.org/0000-0003-4739-4302ТоропцоваН. В.ToroptsovaN. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-2809-0197ДобровольскаяО. В.DobrovolskayaO. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0003-0961-9785ДеминН. В.DeminN. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0001-6759-8367НикитинскаяО. А.NikitinskayaO. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2021180220211513237Copyright © Ефремова А.О., Торопцова Н.В., Добровольская О.В., Демин Н.В., Никитинская О.А., 20212021Ефремова А.О., Торопцова Н.В., Добровольская О.В., Демин Н.В., Никитинская О.А.Efremova A.О., Toroptsova N.V., Dobrovolskaya O.V., Demin N.V., Nikitinskaya O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1097

Цель исследования – определить частоту высокой и очень высокой 10-летней вероятности переломов по алгоритму FRAX® у больных с системной склеродермией (ССД) для оценки потребности в антиостеопоротическом лечении.

Пациенты и методы

Пациенты и методы. В исследование включено 136 больных ССД (110 женщин и 26 мужчин, средний возраст 59,3±7,5 года). Проведены анкетирование пациентов с подсчетом риска основных переломов по алгоритму FRAX® и двухэнергетическая рентгеновская денситометрия поясничного отдела позвоночника и проксимального отдела бедра.

Результаты и обсуждение

Результаты и обсуждение. Очень высокий риск переломов имелся у 41,2% обследованных, высокий риск – у 10,3%, а низкий – у 48,5%. Остеопороз (ОП) хотя бы в одной области выявлен у 41,2% больных. Среди лиц с низким риском переломов ОП диагностирован у 18,2%, а переломы в анамнезе – у 10,6%. Всего в назначении антиостеопоротического лечения нуждались 65,4% больных ССД.

Заключение

Заключение. По данным комплексной оценки, лечение ОП и профилактика переломов были показаны 65,4% больных ССД. Алгоритм FRAX® менее информативен у мужчин, нуждающихся в терапии, чем у женщин.

Objective

Objective: to estimate the high and very high Frax® 10-year probabilities of fractures in patients with systemic sclerosis (SSc) to assess the need for anti-osteoporotic treatment.

Patients and methods

Patients and methods. The investigation enrolled 136 SSc patients (110 women and 26 men; mean age, 59.3±7.5 years). The patients underwent a questionnaire survey, by calculating the risk of major fractures with the FRAX® algorithm and dual-energy X-ray densitometry (DXA) of the lumbar spine and proximal femur.

Results and discussion

Results and discussion. There was a very high risk of fractures in 41.2% of the examinees, a high risk in 10.3%, and a low risk in 48.5%. Osteoporosis (OP) in at least one area was detected in 41.2% of the patients. Among the persons with a low risk of fractures, OP was diagnosed in 18.2%, whereas 10.6% had a history of fractures. A total of 65.4% of SSc patients needed anti-osteoporotic treatment.

Conclusion

Conclusion. According to the comprehensive assessment, OP treatment and fracture prevention were indicated for 65.4% of SSc patients. The FRAX® algorithm is less informative in males who need therapy than in females.

системная склеродермияостеопорозFRAX®остеопоротический переломриск переломаsystemic sclerosisosteoporosisFRAX®osteoporotic fracturerisk for fractureReferencesZhong L, Pope M, Shen Y, et al. Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. Int J Rheum Dis. 2019 Dec;22(12):2096-2107. doi: 10.1111/1756-185X.13716. Epub 2019 Oct 16.Zhong L, Pope M, Shen Y, et al. Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. Int J Rheum Dis. 2019 Dec;22(12):2096-2107. doi: 10.1111/1756-185X.13716. Epub 2019 Oct 16.Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000 Dec;39(12): 1383-9. doi: 10.1093/rheumatology/39.12.1383.Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000 Dec;39(12): 1383-9. doi: 10.1093/rheumatology/39.12.1383.Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med. 2016 Jan 19;3(1):e000098. doi: 10.1136/lupus-2015-000098. eCollection 2016.Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med. 2016 Jan 19;3(1):e000098. doi: 10.1136/lupus-2015-000098. eCollection 2016.Lee JH, Sung YK, Choi CB, et al. The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016 Feb 24;17:98. doi: 10.1186/s12891-016-0952-8.Lee JH, Sung YK, Choi CB, et al. The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016 Feb 24;17:98. doi: 10.1186/s12891-016-0952-8.Hauser B, Riches PL, Wilson JF, et al. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2014 Oct;53(10):1759-66. doi: 10.1093/rheumatology/keu162. Epub 2014 Apr 24.Hauser B, Riches PL, Wilson JF, et al. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2014 Oct;53(10):1759-66. doi: 10.1093/rheumatology/keu162. Epub 2014 Apr 24.Balasubramanian A, Wade SW, Adler RA, et al. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients with Selected Conditions. J Bone Miner Res. 2018 Oct; 33(10):1881-8. doi: 10.1002/jbmr.3523.Balasubramanian A, Wade SW, Adler RA, et al. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients with Selected Conditions. J Bone Miner Res. 2018 Oct; 33(10):1881-8. doi: 10.1002/jbmr.3523.Omair MA, Pagnoux C, McDonald-Blumer H, et al. Low bone density in systemic sclerosis. A systematic review. J Rheumatol. 2013 Nov;40(11): 1881-90. doi: 10.3899/jrheum.130032. Epub 2013 Sep 15.Omair MA, Pagnoux C, McDonald-Blumer H, et al. Low bone density in systemic sclerosis. A systematic review. J Rheumatol. 2013 Nov;40(11): 1881-90. doi: 10.3899/jrheum.130032. Epub 2013 Sep 15.Добровольская ОВ, Демин НВ, Смирнов АВ и др. Состояние минеральной плотности костной ткани и потребность в противоостеопоротической терапии у женщин в постменопаузе с системной склеродермией. Медицинский совет. 2019;(9):72-9.Dobrovol'skaya OV, Demin NV, Smirnov AV, et al. The state of bone mineral density and the need for anti-osteoporotic therapy in postmenopausal women with systemic scleroderma. Meditsinskii sovet. 2019;(9):72-9. (In Russ.).World Health Organization. Assessment of osteoporosis at the primary health care level. Geneva: WHO; 2007. www.who.int/chp/topics/rheumatic/en/index.htmlWorld Health Organization. Assessment of osteoporosis at the primary health care level. Geneva: WHO; 2007. www.who.int/chp/topics/rheumatic/en/index.htmlNguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008 Oct;19(10): 1431-44. doi: 10.1007/s00198-008-0588-0. Epub 2008 Mar 7.Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008 Oct;19(10): 1431-44. doi: 10.1007/s00198-008-0588-0. Epub 2008 Mar 7.Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009 Nov 19;339:b4229. doi: 10.1136/bmj.b4229.Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009 Nov 19;339:b4229. doi: 10.1136/bmj.b4229.Kanis JA; WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK; 2008.Kanis JA; WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK; 2008.Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008 Apr;19(4):385-97. doi: 10.1007/s00198-007-0543-5. Epub 2008 Feb 22.Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008 Apr;19(4):385-97. doi: 10.1007/s00198-007-0543-5. Epub 2008 Feb 22.Kanis JA, Cooper C, Rizzoli R, et al; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan; 30(1):3-44. doi: 10.1007/s00198-018-4704-5. Epub 2018 Oct 15.Kanis JA, Cooper C, Rizzoli R, et al; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan; 30(1):3-44. doi: 10.1007/s00198-018-4704-5. Epub 2018 Oct 15.Никитинская ОА, Торопцова НВ, Демин НВ. Факторы риска и минеральная плотность кости в прогнозировании риска перелома у женщин в постменопаузе. Современная ревматология. 2016;10(3):23-8. doi: 10.14412/1996-7012-2016-3-23-28Nikitinskaya OA, Toroptsova NV, Demin NV. Risk factors and bone mineral density in predicting the risk of fracture in postmenopausal women. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(3):23-8. (In Russ.). doi: 10.14412/1996-7012-2016-3-23-28Баранова ИА, Белая ЖЕ, Гассер РВ и др. Остеопороз. Руководство для врачей. Москва; 2016.Baranova IA, Belaya ZhE, Gasser RV, et al. Osteoporoz. Rukovodstvo dlya vrachei [Osteoporosis. Guide for doctors]. Moscow; 2016.Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020 Jan;31(1):1-12. doi: 10.1007/s00198-019-05176-3. Epub 2019 Nov 13.Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020 Jan;31(1):1-12. doi: 10.1007/s00198-019-05176-3. Epub 2019 Nov 13.Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-37. doi: 10.1002/art.40137. Epub 2017 Jun 6.Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-37. doi: 10.1002/art.40137. Epub 2017 Jun 6.Lai EL, Huang WN, Chen HH, et al. Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. Lupus. 2019 Jul; 28(8):945-53. doi:10.1177/0961203319855122. Epub 2019 Jun 9.Lai EL, Huang WN, Chen HH, et al. Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases. Lupus. 2019 Jul; 28(8):945-53. doi:10.1177/0961203319855122. Epub 2019 Jun 9.

The authors declare that there are no conflicts of interest present.